导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.08% | 2441/4773 |
| 近一周 | -0.83% | 1319/5465 |
| 近一月 | -1.67% | 1228/5421 |
| 近一季 | -10.99% | 3854/5231 |
| 近半年 | -8.31% | 3485/4920 |
| 近一年 | 1.76% | 2417/4394 |
| 近两年 | 78.73% | 865/2954 |
| 近三年 | 41.42% | 731/2253 |
| 成立以来 | 127.74% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.54% 1248/4961 |
13.10% 2061/5312 |
- - |
- - |
| 2025 | 35.52% 985/4813 |
6.61% 609/3635 |
4.99% 668/4076 |
21.24% 1828/4524 |
-0.13% 2376/4813 |
| 2024 | 6.88% 1714/3463 |
-5.51% 1917/2808 |
-5.53% 1741/3014 |
16.28% 1489/3129 |
2.97% 871/3463 |
| 2023 | 1.02% 373/2656 |
12.09% 316/2280 |
-1.16% 447/2385 |
-6.20% 1452/2515 |
-2.79% 532/2655 |
| 2022 | -13.01% 311/2207 |
-12.24% 593/1919 |
7.25% 503/2016 |
-10.63% 434/2113 |
3.41% 696/2208 |
| 2021 | 28.22% 84/1822 |
2.38% 220/1255 |
9.50% 548/1330 |
5.43% 273/1466 |
8.48% 152/1822 |
| 2020 | 37.76% 374/1250 |
1.52% 143/1028 |
24.41% 170/1067 |
8.48% 712/1164 |
0.56% 1054/1184 |
| 2019 | 42.74% 207/1092 |
28.87% 292/739 |
-3.28% 377/788 |
3.87% 230/850 |
10.25% 151/918 |
| 2018 | -29.25% 448/834 |
- - |
-13.16% 431/631 |
-8.90% 497/660 |
-10.44% 196/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商中证1000指数增强A VS. 长安沪深300非周期A(740101) |